NASDAQ: RPIDRapid Micro Biosystems Inc Stock
$0.82-0.02 (-2.38%)
Updated Sep 9, 2024
RPID Price
$0.82
Fair Value Price
N/A
Market Cap
$34.98M
52 Week Low
$0.58
52 Week High
$1.19
P/E
-0.7x
P/B
0.37x
P/S
1.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.71M
Earnings
-$50.46M
Gross Margin
-14.2%
Operating Margin
-220.08%
Profit Margin
-204.2%
Debt to Equity
0.24
Operating Cash Flow
-$45M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RPID Overview
Rapid Micro Biosystems Incorporated offers automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship platform, Growth Direct, automates manual microbial quality control (MQC), testing workflows used in pharmaceutical manufacturing operations. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. Rapid Micro Biosystems was incorporated in 2006 and is headquartered in Lowell, MA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RPID scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPID is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RPID is good value based on its book value relative to its share price (0.37x), compared to the US Medical Devices industry average (4.06x)
P/B vs Industry Valuation
RPID is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RPID due diligence checks available for Premium users.
Be the first to know about important RPID news, forecast changes, insider trades & much more!
RPID News
Valuation
RPID price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.7x
Industry
42.41x
Market
24.05x
RPID price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
4.06x
RPID is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPID's financial health
Profit margin
Revenue
$6.6M
Net Income
-$12.6M
Profit Margin
-190.1%
RPID's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RPID's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$117.1M
Liabilities
$22.5M
Debt to equity
0.24
RPID's short-term assets ($98.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPID's short-term assets ($98.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPID's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.1M
Investing
$24.8M
Financing
-$10.0k
RPID's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RPID vs Medical Device Stocks
Rapid Micro Biosystems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.